Henlius Shareholders Unanimously Approve 2025 Reports and Profit Distribution

TipRanks18:56

Fuhong Hanlin rose in the afternoon trading after the recent completion of patient enrollment for the H drug Hansizhuang's bridging trial in Japan for first-line treatment of small cell lung cancer.

Fuhong Hanlin (02696.HK) surged over 4% in the afternoon session. As of the time of writing, it was up 3.19%, trading at HKD 69.65, with a turnover of HKD 37.252 million.

Zhitong FinanceMay 18 14:00

HKEX Announcement Insights | Alibaba-W released its annual financial results, with revenue reaching RMB 1,023.67 billion, representing a year-on-year increase of 3%.

Alibaba-W released its annual results, with revenue reaching RMB 1,023.67 billion, a year-on-year increase of 3%. Tencent reported steady growth in revenue and net profit for the first quarter, with non-IFRS attributable profit to equity holders amounting to RMB 67.905 billion, marking an 11% year-on-year increase.

Zhitong FinanceMay 14 09:00

Henlius (02696): The Phase 1 clinical study of HLX97 in patients with advanced/metastatic solid tumors has completed the first patient dosing within mainland China.

Henlius Biotech, Inc. (02696) announced that recently, the Phase 1 clinical study of HLX97 (KAT6A/B small molecule inhibitor) (HLX97), independently developed by the company, has completed the first patient dosing in China (excluding Hong Kong, Macao, and Taiwan regions) for patients with advanced/metastatic solid tumors.

Zhitong FinanceMay 13 17:03

Henlius (02696.HK): The Phase 1 clinical study of HLX97 in patients with advanced/metastatic solid tumors has completed the first patient dosing within mainland China.

Gelonghui, May 13th: Henlius Biotech (2696.HK) announced that the Phase 1 clinical study of HLX97 (KAT6A/B small molecule inhibitor), a self-developed product by the company for treating advanced/metastatic solid tumors, has completed the first patient dosing in mainland China (excluding Hong Kong, Macao, and Taiwan regions).

Gelonghui FinanceMay 13 17:01

Henlius (02696.HK): The Phase 1 clinical trial application for HLX05-N (a biosimilar of cetuximab injection, recombinant anti-EGFR chimeric monoclonal antibody injection) for the treatment of metastatic colorectal cancer (mCRC) has been approved by the U.

Gelonghui, May 10th: Fosun Henlius (02696.HK) announced that the company's self-developed Cetuximab Injection Biosimilar HLX05-N (Recombinant Anti-EGFR Chimeric Monoclonal Antibody Injection) has received approval from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to conduct a Phase 1 clinical trial for the treatment of metastatic colorectal cancer (mCRC). The company plans to initiate the Phase 1 clinical trial in the United States once conditions are met. HLX05-N is a biosimilar of Cetuximab Injection independently developed by the company, intended for the treatment of metastatic colorectal cancer.

Gelonghui FinanceMay 10 18:27